<DOC>
	<DOCNO>NCT00378755</DOCNO>
	<brief_summary>1 . Primary Objective To assess response rate sequential VAD ( Vincristine , Adriamycin , Dexamethasone ) VTD ( Velcade , Thalidomide , Dexamethasone ) induction therapy first line treatment patient multiple myeloma 2 . Secondary Objectives 1 . To assess progression free survival , duration response , overall survival patient give sequential VAD VTD induction follow high dose therapy autologous stem cell transplantation maintenance treatment Velcade 2 . To assess toxicity sequential VAD VTD induction chemotherapy , high dose therapy autologous stem cell transplantation , maintenance treatment Velcade .</brief_summary>
	<brief_title>Sequential VAD VTD Followed HDT With ASCT Velcade Maintenance NDMM</brief_title>
	<detailed_description>1 . Overview study design This study aim assess efficacy toxicity sequential VAD VTD induction follow high dose therapy autologous stem cell transplantation maintenance treatment velcade first line treatment patient multiple myeloma . This study conduct open , multi-center , single arm , prospective phase 2 study . 2 . Sample size determination The expect response rate sequential VAD VTD induction chemotherapy first line treatment patient multiple myeloma 80 % . By use Flemming ’ single stage design (  error : 0.05 ,  error : 0.2 ) , 55 evaluable patient need prove hypothesis . If withdrawal rate 10 % , enrollment total 62 patient need . 3 . Duration Study One year enrollment need ( 2006.03.1-2007.02.28 ) . At least 24 month follow-up patient enrol last time need .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1.Previously untreated newly diagnose patient MM ( stage IIIII ) 2.Age &lt; 65 3.Eastern Cooperative Oncology Group Performance Status 01 4.EF &gt; 50 % , FVC FEV &gt; 50 % , DLCO &gt; 50 % 5.Platelet count ≥ 100 x 109/L ( pretreatment platelet transfusion allow , transfusion treatment permit ) , hemoglobin ≥ 8 g/dL ( ≥ 4.96 mol/L ) , Prior RBC transfusion recombinant human erythropoietin use allow ) , absolute neutrophil count ( ANC ) ≥ 1.0 x 109/L 6.Adequate liver function ( bilirubin &lt; UNL ( Upper Normal Limit ) x 2 ALT/AST &lt; UNL x 3 ) 7.Adequate renal function ( serum creatinine &lt; UNL x 1.5 creatine clearance &gt; 60 ml/min ) 8.Signed informed consent , ability follow protocol 1 . History allergic reaction attributable compound contain boron mannitol 2 . Known hypersensitivity thalidomide dexamethasone 3 . Peripheral neuropathy neuropathic pain Grade 2 high define NCI CTCAE version 3 4 . Uncontrolled severe cardiovascular disease , include MI within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 5 . Acute severe infection require antibiotic therapy 6 . Previous cancer history ( except situ carcinoma cervix basal cell cancer skin ) 7 . Pregnancy breastfeed 8 . Active ulcer detect gastroscopy ( gastroscopy routine patient , patient symptoms ulcer disease and/or history previous ulcer therapy and/or physician 's discretion ) 9 . Previous renal transplantation 10 . Recurrent deep vein thrombosis pulmonary embolism 11 . Uncontrolled diabetes mellitus 12 . Receipt extensive radiation therapy within 4 week ( ( Extensive mean RT 2 anatomic site ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>velcade</keyword>
	<keyword>myeloma</keyword>
	<keyword>VAD regimen</keyword>
	<keyword>Transplantation , Autologous</keyword>
</DOC>